Clinical trials: Reflux Esophagitis
Early Gastric Cancer, Adenocarcinoma of the Stomach
SPADE Clinical Trial.
Purpose: This multicenter, prospective, single-arm phase 2 clinical trial aims to evaluate the safety, feasibility, and clinical outcomes of the SPADE operation (Spade-Shaped Anastomosis) in patients undergoing laparoscopic or…
- Conditions
- Early Gastric Cancer, Adenocarcinoma of the Stomach, Proximal Gastric Cancer, SPADE Operation
- Trial name
- SPADE (NCT07892183)
- Testing
- Spade-Shaped Anastomosis after Laparoscopic or Robotic Proximal Gastrectomy Using Double Suture Anchoring between the Posterior Wall of the Esophagus and the Anterior Wall of the Stomac
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- National Cancer Center, Korea
Gastro-esophageal Reflux Disease
Epithelial Damage in GERD
The purpose of this study is to characterize and compare epithelial damage in patients with erosive esophagitis and non-erosive reflux disease.
- Trial name
- NCT01867931
- Where
- Netherlands
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Healthy Volunteers
Single-dose and Multiple-dose X842 Phase 1 Study
The purpose of this study is to evaluate the safety and tolerability of X842 after administration of single and multiple doses in healthy subjects
- Trial name
- NCT04293965
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Food Effect
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Erosive Esophagitis
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically…
- Trial name
- NCT05055128
- Testing
- X842, X842 Dummy, Lansoprazole
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Cinclus Pharma Holding AB
Eosinophilic Esophagitis
Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies
The purpose of this research study is to compare the safety and effectiveness of three commonly used techniques for delivering anesthesia during a procedure known as esophagogastroduodenoscopy.
- Trial name
- NCT02038894
- Testing
- Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Non-erosive Reflux Disease, Erosive Esophagitis
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
- Trial name
- NCT05890001
- Testing
- BLI5100
- Where
- 60 sites in United States
- Volunteers
- 400 people
- Sponsor
- Braintree Laboratories
Gastroesophageal Reflux
A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis
The purpose of this study is to evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis (ERE).
- Trial name
- REPAIR (NCT02755753)
- Testing
- Lansoprazole, Rebamipide
- Where
- 5 sites in China, South Korea
- Volunteers
- 143 people
- Sponsor
- YongChan Lee
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven…
- Trial name
- NCT00251693
- Testing
- Dexlansoprazole MR, Lansoprazole
- Where
- 140 sites in United States, Australia and 13 more
- Volunteers
- 2,038 people
- Sponsor
- Takeda
Esophageal Diseases, Achalasia
PRospective Registry of Esophageal Motility
Digestive physiopathology is a branch of gastroenterology aiming to study patients with upper GI symptoms, mainly gastro-esophageal, potentially indicating the presence of Gastroesophageal Reflux Disease (GERD)/Barrett Esophagus…
- Conditions
- Esophageal Diseases, Achalasia, Eosinophilic Esophagitis, Motility Disorder
- Trial name
- PREM (NCT07506746)
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Gastroesophageal Reflux
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.
- Trial name
- NCT00229424
- Testing
- Lafutidine, Famotidine
- Where
- Japan
- Volunteers
- 325 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Eosinophilic Esophagitis (EoE)
BURDEN OF ESOPHAGEAL CANCER IN EOSINOPHILIC ESOPHAGITIS (ESCAPE STUDY)
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus that can lead to symptoms such as dysphagia and food impaction.
- Trial name
- ESCAPE (NCT07102329)
- Where
- Italy
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Esophagitis, Reflux, Esophagitis, Peptic
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255151
- Testing
- Dexlansoprazole MR
- Where
- 100 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive…
- Trial name
- NCT00658775
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 1,069 people
- Sponsor
- Eisai Inc.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Esophageal Diseases, Esophagitis
Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
GERD is common in Indian population and the normative data which is used to diagnose \& manage GERD and its complications are based on western data which is not validated in the Indian population.
- Conditions
- Esophageal Diseases, Esophagitis, Reflux Disease
- Trial name
- NCT05004155
- Testing
- 24 hour pH & impedance monitoring
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
GERD
A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Primary Objective To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.
- Trial name
- NCT06953986
- Testing
- Vonoprazan, Esomeprazole 40mg
- Where
- India
- Volunteers
- 414 people
- Sponsor
- Asian Institute of Gastroenterology, India
Reflux Esophagitis (RE)
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
- Trial name
- NCT06850480
- Testing
- JP-1366 simulation tablets, Esomeprazole Magnesium (Nexium) simulation tablets
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux, Heartburn
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
- Conditions
- Gastroesophageal Reflux, Heartburn, Dyspepsia
- Trial name
- NCT00243724
- Testing
- Esomeprazole
- Where
- 10 sites in Canada
- Volunteers
- 350 people
- Sponsor
- AstraZeneca